DexCom (NASDAQ: DXCM) is a big name in diabetes care. Its continuous glucose monitors (CGMs) help people track their blood glucose levels.

But the stock has been performing poorly this year amid falling growth (the company projects an organic growth rate of around 11% to 13%, far lower than in the past). Investors have also been growing concerned about its prospects, especially if weight loss drugs can lead to a reduction in diabetes cases in the long run.

Down more than 40% this year, DexCom's stock has been in a tailspin. But while it might seem like a troubling time to own the stock, here are three reasons I would consider buying it.

Continue reading

Source Fool.com